April 4, 2024 11:53 PM EDTUpdated 01:00 PM
Financing
Startups

Con­tineum prices $110M IPO as IPF and neu­ro drugs ad­vance

Kyle LaHucik

Senior Reporter

An­oth­er San Diego biotech will go pub­lic Fri­day morn­ing, with Con­tineum Ther­a­peu­tics mak­ing its Nas­daq de­but to fund its Phase 2 neu­ro drug and ear­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times